Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss. [PDF]
Allinovi M +4 more
europepmc +1 more source
Malaysian Expert Consensus Guidelines for the Diagnosis and Management of Multiple Myeloma: A Modified Delphi Approach. [PDF]
Gan GG +10 more
europepmc +1 more source
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. [PDF]
Facon T +31 more
europepmc +1 more source
High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients. [PDF]
Hwa YL +21 more
europepmc +1 more source
Correction: Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability. [PDF]
Horigome Y +6 more
europepmc +1 more source
Subcutaneous Daratumumab in Recurrent Posttransplant Focal Segmental Glomerulosclerosis: A Report of 2 Cases. [PDF]
Aleš Rigler A +3 more
europepmc +1 more source
CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma. [PDF]
Banerjee R.
europepmc +1 more source
Case Report: Zanubrutinib for refractory immune thrombotic thrombocytopenic purpura. [PDF]
De Angelis AD +6 more
europepmc +1 more source
Histopathological improvement in kidney AL amyloid deposits following daratumumab-based chemotherapy and autologous peripheral blood stem cell transplantation: a case report. [PDF]
Hirashio S +5 more
europepmc +1 more source

